Gestalte GoConqr mit. Was sollen wir als Nächstes hinzufügen?

Karteikarten

Stroke and TIA

Natalie Thurtle Principles of EM and Medicine Postgraduate Englisch 37 Karten

COW visual

Karten in diesem Stapel (37)

  1. 1COW visualCOW visual
  2. 2NICS TIA and CVA bundleRapid initial stroke screen
    ABCD2 if TIA suspected
    Urgent CT / MRI
    NBM until bedside swallow screen
    Aspirin if haemorrhage excluded
    Monitoring and neuro obs
  3. 3ABCD2Age > 60 = 1
    BP > 140/90 = 1
    Clinical features:
    - unilateral weakness = 2
    - speech impairment w/out weakness = 1
    Duration of symptoms:
    > 1 hr = 2
    - 10-59 min = 1
    DM = 1
  4. 4Scoring ABCD26 or 7 (high risk) - 2-day stroke risk 8%
    - 7 day stroke risk 25 - 30%
    4 or 5 (mod risk) - 2-day stroke risk 4%
    - 7 day stroke risk 20-25%
    0-3 (low risk) - 2-day stroke risk 1%
    - 7 day stroke risk 0-15%
    NICS dichotomises to high/low risk
    - score > 4 = high risk
    - score < 4 = low risk
  5. 5Antiplatelet in CVAAspirin only proven antiplatelet for CVA
    - CAST and IST trials confirm this
    150 mg/day reduces risk of CVA by 20-30%
    - 50% benefit occurs in first 2/52
    Rx 1,000 AF pts with aspirin prevents 15 CVA per year
    Clopidogrel and aspirin/dipyridamole
    - may be more effective than aspirin alone
    - may reduce risk of vascular events in AF
  6. 6Anticoagulation in AFWarfarin reduces stroke in AF by 2/3
    Based on risks of embolism and bleeding
    Rx 1,000 AF pts prevents 30 CVAs, causes at least 2 major haemorrhage/yr
    Aspirin if warfarin CI if no renal failure
  7. 7MCA syndrome ?embolic or thromboticUsually embolic
  8. 8Common features MCA syndromeContralateral
    - hemiplegia
    - hemisensory loss
    - homonymous hemianopia
    Eyes deviated to side of lesion
    Face and arm weakness > leg
    Distal occlusion leads to more limited signs
  9. 9ACA syndromeParalysis of contralateral leg and foot
    Confusion
    Abulia - diminished motivation
    Grasp reflex present
    Behavioural disturbance
    Urinary incontinence
  10. 10PCA syndromeHemianopia
    Quadrantanopias
    Cortical blindness
    Memory loss
    Dyslexia
    Hemisensory loss
    Ipsilateral III palsy
  11. 11Vertebrobasilar infarctionCerebellar and brain stem lesions:
    Ataxia
    Dizziness
    N/V
    Nystagmus
    Wide variety of CN palsies
    Internuclear ophthalmoplegia
  12. 12Internuclear ophthalmoplegiaEye fails to adduct
    Lesion in medial longitudinal faciculus
  13. 13Lateral medullary syndromeIpsilateral:
    - UMN VIIth, IXth and Xth
    - Horner’s
    Contralateral spinothalamic loss (pain and temperature)
    Conjugate gaze palsy
  14. 14Wallenburg's syndromePosterior inferior cerebellar artery disease
    Cerebellar signs
    Dysphagia
    Loss of pain and temp sensation
    Weakness and paralysis
  15. 15ROSIERGCS
    BP
    BSL - if <3.5 reassess
    LOC or syncope? -1
    Seizure? -1
    New asymmetrical facial weakness? 1
    New asymmetrical arm weakness? 1
    New asymmetrical leg weakness? 1
    Speech disturbance? 1
    Visual field defect? 1
  16. 16ROSIER scores<=0 Stroke unlikely but not completely excluded
    Designed to exclude stroke mimics
  17. 17FASTFace Arm Speech Test
  18. 18NIH stroke scaleUsed in various stroke trials
    Modified and simplified for ED use as Cincinnati prehospital stroke scale
    Rapid and reproducible
    Measures impairment caused by stroke
    Allows comparison of deficit over time
  19. 19CT for infarctionUsually no abnormality in first few hrs
    - sens 50% within 6 hrs
    - spec > 95%
    Early changes usually indicate major infarction
  20. 20Features of infarction on CTHELLO LP
    Hyperdense MCA or other cerebral artery
    - 100% specific, 50% sensitive for MCA occlusion
    Effacement of cortical sulci
    Local mass effect
    Loss of insular ribbon
    Obscuration of lentiform nucleus
    Parenchymal hypodensity
    Loss of grey/white differentiation
  21. 21BP control in haemorrhagic strokeMay reduce haematoma volume
    ICH ?less ischaemic penumbra than thrombotic, so hazards reduced
    If sBP 200 or MAP 150, consider aggressive reduction
    If sBP 180 or MAP 130 and ICP up, consider monitoring ICP and reducing BP while maintaining CPP > 60 mmHg
    If ICP not up, consider reducing BP to MAP 110 or < 160/90
    High risk for haematoma growth: SBP 140
  22. 22Efficacy of HASU46/1,000 patients spared death or dependency by stroke unit care
  23. 23Primary ICH managementCerebellar > 3 cm should go to OT
    For non - cerebellar haemorrhages:
    - surgery not commonly employed
    - trial results do not support
    Blood in ventricles associated with high mortality
    - may be related to obstructive hydrocephalus
    - drainage of CSF through ventricular catheters reduces ICP, but frequently clots
  24. 24Modified Rankin0 No symptoms
    1 No significant disability despite symptoms; able to carry out ADLs
    2 Slight disability; unable to carry out all ADL, but independent
    3 Mod disability; requiring help, but able to walk without assistance
    4 Mod severe disability; unable to walk/ADLs without assistance
    5 Severe; bedridden, incontinent and requiring constant nursing care
    6 Dead
  25. 25% of strokes that are ICH10-15%
  26. 26Primary haemorrhage80-90%
    Spontaneous rupture of small vessels damaged by hypertension or amyloid
    Charcout-Bouchard micro-aneurysms of penetrating arteries of
    - MCA
    - basilar
    - Circle of Willis
  27. 27Secondary HaemorrhageMinority with vascular abnormalities eg, AVMs, aneurysms
    Haemorrhagic transformation assoc with:
    tPA (greatest RF)
    Cardioembolic strokes
    ICA occlusion
    Clopidogrel and aspirin
    Anticoagulation
    Hypertension
    Hyperglycaemia
  28. 28Thalamic haemorrhage clinical featuresContralateral hemiplegia
    Eyes down and in
    Unequal pupils
    Absent light reflexes
    Ipsilateral Horner’s
    Lateral gaze defects
    Prominent sensory deficit
    Aphasia
  29. 29Pontine haemorrhage clinical featuresDeep coma with quadriplegia
    Pin point pupils
    Decerebrate rigidity
    Hyperpnoea
    Hypertension
    Hyperhydrosis
  30. 30Commonest site of primary haemorrhagePutaminal
    Eyes deviate to contralateral side
    Contralateral hemiplegia
  31. 31Key issues in the tPA debateValidity of key study results
    Accurate representation of data and selective reporting of results
    Role of industry in research
    Level of evidence required to institute significant practice change
    Allocation of resources between acute stroke care and other care
  32. 32Dosing tPA (alteplase) for strokeCommenced within 3 hrs of onset:
    0.9 mg/kg (90 mg max)
    10% bolus
    90% over 60 min
  33. 33Summary of tPA (alteplase) trials12 trials published on thrombolysis (mostly alteplase)
    2 RCTs found a benefit as defined by primary outcome measures (NINDS, ECASS-3)
    2 were stopped early because of harm (ATLANTIS)
    8 remaining studies had negative findings for primary outcome (IST-3 had a positive secondary outcome)
    Supported by meta-analysis based on the above studies
    Supported by large industry funded registry data-sets
  34. 34Problems with trialsMissing data from studies stopped early
    Heterogeneity calculations strongly suggest data pooling inappropriate
    Imbalances in baseline stroke severity (NINDS, ECASS-3)
    Use of subjective outcome measures (MRS)
    Manufacturer involvement in only blinded studies with benefit (NINDS, ECASS-3)
    IST-3 - open-label subject to bias with FU calls
    Meta-analysis flawed as based on flawed
    Controversy over time window - poor correlation in IST-3; apparent window ?more severe strokes likely to present early
  35. 35Pros - tPA in StrokeNNT ~ 11 with persisting benefits in terms of neuro outcomes (at least 3/12)
    No increase in mortality overall
    Registries suggest safety similar to trials
    Supported by many professional societies
    Little disruption to ED if additional resources provided by stroke team
  36. 36Cons - tPA in strokeDefinite risk of early ICH and death
    2 pos trials suffer from baseline imbalance
    2 pos trials - conflicts of interest
    Few patient studies (despite mutliple meta-analyses)
    Majority of studies show no overall benefit
    Systematic rvs based on flawed studies
    5% of stroke pts are eligible for lysis
    Potential disruption of ED service
    NNT likely inflated by pts rx <90 minutes
    Difficulty distinguishing stroke mimics
    Consent problematic
    Stroke prevention and rehab more cost-effective
  37. 37Criteria for tPA in stroke - all must be metNIHSS < 25
    CT shows < 1/3 MCA territory
    Valid consent able to be obtained
    tPA possible within 3 hrs of onset
    INR < 1.7
    No aspirin and clopidogrel
    No NOAC in previous 48 hrs

Informationen

Beschreibung
Postgraduate Principles of EM and Medicine Karteikarten am Stroke and TIA, erstellt von Natalie Thurtle am 20/04/2015.
Erstellt von
Natalie Thurtle
Aufrufe
3
Bewertung

Mehr zu Transient Ischemic Attack

Feedback

Worum geht es?

Was sollen wir als Nächstes hinzufügen?